You are here

Article info

Article menu
Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Case report
Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness

Authors

  • Manuel Alfredo Podestà Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, ItalyUnit of Nephrology and Dialysis, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy PubMed articlesGoogle scholar articles
  • Barbara Ruggiero Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, ItalyDivision of Nephrology, Department of Pediatric Subspecialties, Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy PubMed articlesGoogle scholar articles
  • Giuseppe Remuzzi Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy PubMed articlesGoogle scholar articles
  • Piero Ruggenenti Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, ItalyUnit of Nephrology and Dialysis, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Giuseppe Remuzzi; giuseppe.remuzzi{at}marionegri.it
View Full Text

Citation

Podestà MA, Ruggiero B, Remuzzi G, et al
Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness
BMJ Case Reports CP 2020;13:e232896.

Publication history

  • Accepted December 12, 2019
  • First published January 23, 2020.
Online issue publication 
February 17, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.